Community Perspective on Pancreatic Enzyme Replacement Therapy in Cystic Fibrosis
Authors:
- 6 September 2022
- journal article
- research article
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 75 (5) , E94-E97
Abstract
People with cystic fibrosis (CF) and exocrine pancreatic insufficiency must take pancreatic enzyme replacement therapy (PERT) to prevent malnutrition and gastrointestinal (GI) symptoms. Finding better ways to manage GI complaints is a high priority for the CF community. We fielded a survey to assess the perspective of people affected by CF regarding symptoms attributed to and challenges associated with current PERT, to identify factors that affect participation in PERT studies, and to understand attitudes toward an outcome measure that could be an alternative to the coefficient of fat absorption test. Persistent GI symptoms are commonly ascribed to PERT. Minimizing time commitment and maximizing patient safety were factors affecting participation in research. We demonstrate 4 generalizable ways to incorporate patient experience early in the research process to aid in development of new medications and help improve study enrollment.Keywords
This publication has 19 references indexed in Scilit:
- Pancreatic insufficiency in Cystic FibrosisJournal of Cystic Fibrosis, 2017
- Increased Fat Absorption From Enteral Formula Through an In‐line Digestive Cartridge in Patients With Cystic FibrosisJournal of Pediatric Gastroenterology and Nutrition, 2017
- Review of 99 self-report measures for assessing well-being in adults: exploring dimensions of well-being and developments over timeBMJ Open, 2016
- Patient involvement in clinical research: why, when, and howPatient Preference and Adherence, 2016
- A positive concept of health – Interviews with patients and practitioners in an integrative medicine clinicComplementary Therapies in Clinical Practice, 2013
- Reducing pill burden and helping with medication awareness to improve adherenceCanadian Pharmacists Journal / Revue des Pharmaciens du Canada, 2013
- Building a measurement framework of burden of treatment in complex patients with chronic conditions: a qualitative studyPatient Related Outcome Measures, 2012
- International phase III trial of liprotamase efficacy and safety in pancreatic-insufficient cystic fibrosis patientsJournal of Cystic Fibrosis, 2011
- Individuals with diabetes preferred that future trials use patient-important outcomes and provide pragmatic inferencesJournal of Clinical Epidemiology, 2011
- Pancreatic Enzyme ProductsPediatric Allergy, Immunology, and Pulmonology, 2010